Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With $35 Million B Round, Trevena to Push GPCR-Targeted Program into Phase II for Acute Heart Failure

This article was originally published in The Pink Sheet Daily

Executive Summary

Four investors returned to back the Duke University spinout, which is developing biased ligand small molecules.

You may also be interested in...



Forest Takes Option On Trevena’s Heart Failure Drug, And Some Equity

Already strong in both CNS and cardiovascular drugs, Forest obtained an option to license the Pennsylvania start-up’s lead program in acute heart failure. In the process, Forest took a stake in Trevena as the young company shifts its focus toward pain drugs based on Nobel Prize-winning research.

Deals Of The Week: Sandoz/Fougera, Abbott/Action Pharma/Zealand, AstraZeneca/Axerion

New company Tolero helps MannKind de-risk a preclinical BTK inhibitor program in a “double-jointed” deal in which the “bio-bucks” eventually could flow in either direction.

Trevena Scores NIH Grant For Research In Major Depression

The biotech has forged a partnership with NIH to discover and begin development of a biased ligand to the delta opioid receptor for the treatment of MDD.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel